MI Cancer Seek (MCS)
Tissue-based whole-exome and whole-transcriptome NGS assay using total nucleic acid from FFPE tumors to detect key biomarkers and support targeted therapy selection.
Casandra.ai provides a unified ordering experience so you can request this test directly from the performing lab, without changing your workflow.
Ordering is available where Casandra has an active integration with the performing lab. Labs that offer this test can connect with us to enable digital ordering.
About this test
MI Cancer Seek (MCS) is an FDA-approved next-generation sequencing assay that performs simultaneous whole exome and whole transcriptome analysis on total nucleic acid from FFPE solid tumors. It detects multiple clinically relevant genomic alterations and expression changes, providing a comprehensive profile to support biomarker-driven treatment decisions in adult and pediatric patients ages 1–22.
Where this test fits
| Indication | Biomarker | Biomarker details | Therapy (Select a therapy to open its FDA-approved testing pathway) |
|---|---|---|---|
| Breast Cancer | PIK3CA | C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y | PIQRAY |
| Colorectal Cancer (CRC) | BRAF | V600E | BRAFTOVI + ERBITUX |
| KRAS and NRAS | wild-type (absence of mutations in exons 2, 3 and 4) | VECTIBIX | |
| Endometrial Carcinoma (EC) | Not MSI-High | Not Microsatellite Instability-High (Not MSI-H) | KEYTRUDA + LENVIMA |
| Melanoma | BRAF | V600E | TAFINLAR, ZELBORAF |
| V600E and V600K | BRAFTOVI + MEKTOVI, COTELLIC + ZELBORAF, TAFINLAR + MEKINIST | ||
| V600E or V600K | MEKINIST | ||
| Non-Small Cell Lung Cancer (NSCLC) | EGFR (HER1) | Exon 19 deletion or exon 21 L858R substitution mutation | GILOTRIF, IRESSA, LAZCLUZE + RYBREVANT, TAGRISSO, TARCEVA, VIZIMPRO |
| Solid Tumors | MSI-High | Microsatellite instability-High | JEMPERLI, KEYTRUDA |
Performing lab
Tissue Lab (03D1019490)
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.
Order this test
If your organization is connected to Casandra, you can place an electronic order for MI Cancer Seek (MCS) directly from your existing workflow.
Casandra connects providers, labs, and sponsored programs so that companion diagnostics can be ordered consistently and documented cleanly, regardless of which system you start from.